Marieke van Son

157 PREDICTION MODELS FOR BF AFTER FOCAL SALVAGE HDR-BT REFERENCES 1. Ward JF, Pagliaro LC, Pisters LL. Salvage Therapy for Radiorecurrent Prostate Cancer. Curr Probl Cancer 2008;32:242– 71. https://doi.org/10.1016/j.currprob- lcancer.2008.10.001. 2. Zelefsky MJ, Kuban DA, Levy LB, Pot- ters L, Beyer DC, Blasko JC, et al. Multi-institutional analysis of long- term outcome for stages T1-T2 pros- tate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327–33. https://doi. org/10.1016/j.ijrobp.2006.08.056. 3. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, et al. The natural history and predictors of outcome following biochemical re- lapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 2015;67:1009–16. https://doi. org/10.1016/j.eururo.2014.09.028. 4. Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, et al. Anal- ysis of Intraprostatic Failures in Patients Treated With Hormonal Therapy and Ra- diotherapy : Implications for Conformal Therapy Planning. Int J Radiat Oncol Biol Phys 2002;53:595–9. 5. Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, et al. Clinically Significant Prostate Cancer Local Recurrence After Ra- diation Therapy Occurs at the Site of Primary Tumor: Magnetic Resonance Imaging and Step-Section Pathology Evidence. Int J Radiat Oncol Biol Phys 2007;69:62–9. https://doi.org/10.1016/j. ijrobp.2007.03.065. 6. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, et al. Ana- tomic Patterns of Recurrence Following Biochemical Relapse in the Dose-Es- calation Era for Prostate Patients Un- dergoing External Beam Radiotherapy. J Urol 2015;194:1624–30. https://doi. org/10.1016/j.juro.2015.06.100. 7. Khoo CC, Miah S, Connor MJ, Tam J, Winkler M, Ahmed HU, et al. A system- atic review of salvage focal therapies for localised non-metastatic radiore- current prostate cancer. Transl Androl Urol 2020;9:1535–45. https://doi. org/10.21037/tau.2019.08.21. 8. Van Son M, Peters M, Moerland M, Kerkmeijer L, Lagendijk J, Van der Voort van Zyp J. Focal salvage treatment of radiorecurrent prostate cancer: A nar- rative review of current strategies and future perspectives. Cancers (Basel) 2018;10:480. https://doi.org/10.3390/ cancers10120480. 9. van Son MJ, Peters M, Moerland MA, La- gendijk JJW, Eppinga WSC, Shah TT, et al. MRI-Guided Ultrafocal Salvage High- Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updat- ed Results of 50 Patients. Int J Radiat Oncol 2020. https://doi.org/10.1016/j. ijrobp.2020.01.023. 10. Stabile A, Orczyk C, Giganti F, Moschi- ni M, Allen C, Punwani S, et al. The Role of Percentage of Prostate-specific An- tigen Reduction After Focal Therapy Using High-intensity Focused Ultra- sound for Primary Localised Prostate Cancer. Results from a Large Multi-in- stitutional Series. Eur Urol 2020. https:// doi.org/https :/ /doi.org/10.1016/j. eururo.2020.04.068. 11. Tan WP, ElShafei A, Aminsharifi A, Khalifa AO, Polascik TJ. Salvage Focal Cryother- apy Offers Similar Short-term Oncologic Control and Improved Urinary Function Compared With Salvage Whole Gland Cryotherapy for Radiation-resistant or Recurrent Prostate Cancer. Clin Geni- tourin Cancer 2019:260–5. https://doi. org/10.1016/j.clgc.2019.11.009. 8